In the present study we evaluated for the first time the therapeutic efficacy of targeting the NLRP3 inflammasome in NDDs using a relevant murine model of AD, the 5XFAD/Rubicon KO mouse, which recapitulates the key features of human disease29–33. This evidence concerns the gene NLRP3 and Alzheimer disease.